BPC-157 for Gut Healing & Digestive Health — Gut
Body Protection Compound for GI healing. Strong preclinical data. Phase II trials exist. ORAL bioavailability UNKNOWN. NOT FDA-approved.
Overview
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from human gastric juice with extensive preclinical gastroprotective evidence. CRITICAL EVIDENCE STATUS: Extensive ANIMAL data (35+ studies) but very limited human trials. Phase II trials (PL-10, PLD-116, PL14736) showed promise for IBD/fistula healing but only ONE Phase I human safety trial exists (2015, results never published). ORAL BIOAVAILABILITY IS COMPLETELY UNKNOWN: BPC-157 is stable in gastric acid for 24+ hours, but surviving digestion ≠ systemic absorption. No published human pharmacokinetic data. Manufacturer bioavailability claims (3% standard, 90% arginate) have NO peer-reviewed support. USER REPORTS for oral GI healing are surprisingly POOR despite theoretical advantage. FDA Category 2 bulk drug (2023). NOT FDA-approved. Anyone using BPC-157 is participating in uncontrolled experimentation.
Indications
- Inflammatory bowel disease (Crohn's, UC) - animal data strong, human trials limited
- Leaky gut syndrome and intestinal permeability - preclinical evidence only
- Gastric and duodenal ulcers - extensive animal data
- NSAID-induced gut damage - animal cytoprotection studies
- Post-surgical gut healing - anastomotic repair in animals
- Fistula healing in Crohn's disease - Phase II trials (limited)
Mechanism of Action
IBD, ulcers, or leaky gut cause mucosal damage, inflammation, and impaired barrier function
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| BPC-157 (compounded) | 500-1000 mcg | Twice daily on empty stomach | BIOAVAILABILITY UNKNOWN - stable in acid but absorption unproven |
| BPC-157 (compounded) | 250-500 mcg | Once or twice daily | Presumably higher bioavailability (no human PK data) |
| BPC-157 (compounded) | 500-1000 mcg | Twice daily | ANECDOTAL dosing - no FDA-approved protocol exists |
| BPC-157 5mg + TB-500 10mg | 1-2 sprays per nostril | Once or twice daily | Crosses blood-brain barrier in animal studies |
Evidence Grade
GRADE C
Safety & Contraindications
- CRITICAL: NOT FDA-approved; very limited human clinical trial data
- Phase I safety trial (2015, 42 volunteers) - results NEVER published
- Extensive preclinical safety data in animals
- ORAL BIOAVAILABILITY completely unknown in humans
- No established oral-to-injectable dosing conversion
- Sold as 'dietary supplement' or 'research chemical' without quality control
- May cause temporary injection site redness if using SC route
- Long-term human safety data does not exist